Verona Pharma to Present at 43rd Annual Canaccord Growth Conference
26 Juillet 2023 - 8:00AM
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the
“Company”), a clinical-stage biopharmaceutical company focused
on respiratory diseases, announces that senior management will
present a company overview at the 43rd Annual Canaccord Growth
Conference on Wednesday, August 9, 2023 at 12:00 PM EDT / 5:00 PM
BST.
A webcast of the event will be available on the
Events and Presentations link on the Investors page of the
Company’s website, www.veronapharma.com.
For further information please contact:
Verona Pharma plc |
US Tel: +1-833-417-0262UK Tel: +44 (0)203 283 4200 |
Victoria Stewart, Senior Director of Investor Relations and
Communications |
IR@veronapharma.com |
Argot PartnersUS Investor Enquiries |
Tel: +1-212-600-1902verona@argotpartners.com |
Ten Bridge CommunicationsInternational / US Media
Enquiries |
Tel:
+1-312-523-5016tbcverona@tenbridgecommunications.com |
Leslie Humbel |
|
About Verona Pharma
Verona Pharma is a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative therapies for the treatment of chronic respiratory
diseases with significant unmet medical needs. If successfully
developed and approved, Verona Pharma’s product candidate,
ensifentrine, has the potential to be the first non-steroidal
therapy for the treatment of respiratory diseases that combines
bronchodilator and anti-inflammatory activities in one compound.
The Company has evaluated nebulized ensifentrine in its Phase 3
clinical program ENHANCE (“Ensifentrine as a Novel inHAled
Nebulized COPD thErapy”) for COPD maintenance treatment.
Ensifentrine met the primary endpoint in both ENHANCE-1 and
ENHANCE-2 trials demonstrating statistically significant and
clinically meaningful improvements in lung function. In addition,
ensifentrine substantially reduced the rate and risk of COPD
exacerbations in pooled analysis from ENHANCE-1 and ENHANCE-2. In
the second quarter of 2023, Verona Pharma submitted a New Drug
Application (“NDA”) to the US Food and Drug Administration (“FDA”)
for ensifentrine for the maintenance treatment of patients with
COPD. Two additional formulations of ensifentrine have been
evaluated in Phase 2 studies for the treatment of COPD: dry powder
inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”).
Ensifentrine has potential applications in cystic fibrosis, asthma
and other respiratory diseases. For more information, please visit
www.veronapharma.com.
Verona Pharma (NASDAQ:VRNA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Verona Pharma (NASDAQ:VRNA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024